Technical Issues Associated With Estimating the Prevalence of HPV-52 in Cervical Intraepithelial Neoplasia

Abstract

HPV52 is one of the most commonly detected genotypes in women with cervical intraepithelial neoplasia (CIN). Some methods for genotyping HPV are, however, biased against detection of HPV52. Current literature on this topic primarily focuses on the earliest consensus primer sets MY09/11 and GP5+/6+, or derivatives thereof. There are now many more genotyping assays in use. Given the importance of HPV52 and CIN, and the recent approval of the nine-valent HPV vaccine including HPV52, we undertook an updated discussion and analysis of HPV52 detection in women with CIN2+ by assay type and geographical region from cohorts published between 2006 and 2016. Little difference in HPV52 prevalence was observed by assay type, except sequencing and restriction fragment length polymorphism methods. The most commonly used genotyping methods in the past decade appear to be consistent for detection of HPV52. However, in longitudinal studies the same assay system should be used where possible.